Sabin Vaccine Institute

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
Friday, April 19, 2024
Education, Science, Mentorship, MenAfriVac, Death, Vaccine, Life, Government, Rising Star Award, Klugman, Basta, Global health, Vaccination, Public, Diarrhea, Neonatal sepsis, Princeton University, Developing country, SAMRC, Meningococcal vaccine, Gold medal, DRS, Child, McGill University, RSV, Tomer Capone, Infection, National academy, Pneumonia, Pregnancy, Publication, Health, Research, Meningococcal disease, Sabin Vaccine Institute, Gold, Rotavirus, Student, Organization, GBS, University of the Witwatersrand, University, Canada Research Chair, Florida Department, CBE, Policy, Fever Dream, Disease, Meningitis, HPV, COVID-19

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Global Typhoid Challenges in Focus at International Conference in Rwanda

Retrieved on: 
Tuesday, December 5, 2023
Drug resistance, Conference, Death, Internet, Research, Fever Dream, Sanitation, Urgency, Sabin Vaccine Institute, Drink, Education, Genetically modified bacteria, Coalition, WASH, Filtration, Climate change, Cat, Water, Weather, Food, Bill, Patient, Hygiene, Salmonella enterica subsp. enterica, Vaccine

KIGALI, Rwanda, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The 13th International Conference on Typhoid & Other Invasive Salmonelloses gets under way today in Kigali, Rwanda, with nearly 350 researchers, healthcare professionals and policymakers meeting to find ways to address the urgent challenges of typhoid and other invasive salmonelloses.

Key Points: 
  • KIGALI, Rwanda, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The 13th International Conference on Typhoid & Other Invasive Salmonelloses gets under way today in Kigali, Rwanda, with nearly 350 researchers, healthcare professionals and policymakers meeting to find ways to address the urgent challenges of typhoid and other invasive salmonelloses.
  • The three-day conference, hosted by the Coalition against Typhoid (CaT), housed at the Sabin Vaccine Institute, is the largest convening of the typhoid research community.
  • Typhoid is a bacterial infection contracted through the consumption of food or beverages contaminated with Salmonella Typhi.
  • There are an estimated 9-24 million cases of typhoid fever globally each year, leading to more than 110,000 deaths.

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

Retrieved on: 
Thursday, October 19, 2023
Biomedical Advanced Research and Development Authority, Guinea, Makerere University Walter Reed Project, Sabin Vaccine Institute, Vaccine, Family, Human services, Kenya Medical Research Institute, Administration for Strategic Preparedness and Response, Viral hemorrhagic fever, Organization, BARDA, United States Department of Health and Human Services, Research, Volunteering, Administration, Development, Epidemic, Disease, Clinical trial, Blood, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Polio, Marburg virus disease, Medical device, Pharmaceutical industry

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
  • “Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa.
  • In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.
  • Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

Sabin Vaccine Institute Leads Public and Private Sector Fight to Prevent HPV and End Cervical Cancer with Global HPV Consortium Launch in Kuala Lumpur

Retrieved on: 
Monday, September 4, 2023
Vaccine, Sabin Vaccine Institute, Consortium, Therapy, Education, HIV, Vaccination, Policy, World Trade Organization, Human papillomavirus infection, Woman, Death, Molina Healthcare, Cervical cancer, Adolescence, HPV, Secretariat, Ecosystem, Health, Notifiable disease, Empowerment, Gender, World Health Organization, Syringe, Birth control

KUALA LUMPUR, Malaysia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus (HPV) and eliminating cervical cancer, launched today in Kuala Lumpur, Malaysia.

Key Points: 
  • KUALA LUMPUR, Malaysia, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus (HPV) and eliminating cervical cancer, launched today in Kuala Lumpur, Malaysia.
  • “We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin.
  • It kills approximately 350,000 women annually, is increasing in frequency, and is highly preventable with the HPV vaccine.
  • “The Consortium is critical for building a better understanding of the impact of HPV and of cervical cancer on women,” said Rt.

Noted Vaccine Researcher Thomas P. Monath Awarded Sabin’s Gold Medal; Cameroon Physician Sangwe Clovis Nchinjoh Receives Rising Star Award

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Arbovirus, Gold medal, United States Army Medical Research Institute of Infectious Diseases, Private sector, Sabin Vaccine Institute, Gold, USAMRIID, Vaccination, Virology, Public, Rising Star, Infection, Yellow fever, Smallpox, DRS, Viral, Research, CDC, Fever Dream, Division, Finan, United States Department of the Army, Korea Disease Control and Prevention Agency, Lassa fever, Health, Knowledge, Viral encephalitis, Science, R, System, MPH, Immunization, MD

WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.

Key Points: 
  • WASHINGTON, June 06, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the 30th Albert B. Sabin Gold Medal Award to Thomas P. Monath, MD, and its Rising Star Award to Sangwe Clovis Nchinjoh, MD, MPH, in a ceremony at Washington D.C.’s National Academy of Sciences building.
  • Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs.
  • Sabin’s Rising Star is awarded to encourage and recognize the next generation of vaccine and immunization leaders.
  • “With his focus on strengthening immunization and health services among some of our most neglected communities, Dr. Nchinjoh exemplifies the spirit behind the Rising Star award,” says Finan.

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

Retrieved on: 
Tuesday, March 21, 2023
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Molecular oncology, GSK, Senior, Sabin Vaccine Institute, IO, Institute of technology, Cancer, United States Air Force Scientific Advisory Board, German Cancer Research Center, German Cancer Aid, Doctor of Philosophy, GlaxoSmithKline Pharmaceuticals, Gujarat Cancer Research Institute, Memorial Sloan Kettering Cancer Center, MD, Patient, Trustee, Heidelberg University, Ipilimumab, Memorial, General surgery, R, FDA, Therapy, Cancer Research Institute, Technical University of Munich, Pharmaceutical industry, Scorpion, Medicine

NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.

Key Points: 
  • NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.
  • Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the role.
  • “Dr.
  • I am looking forward to working with the executive team and fellow Board members to help NextPoint realize its promise to deliver the next IO breakthrough,” said Dr. Hoos.

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, January 12, 2023
Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Finan of Lindisfarne, World Health Organization, Development, Fever, U.S. Department of Commerce Office of Security, Administration, Ebola, Human services, Vaccine, Sabin Vaccine Institute, Partnership, Death, BARDA, ASPR, United States Department of Health and Human Services

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

Key Points: 
  • There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.
  • These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.
  • The country declared the Ebola Sudan outbreak had ended on January 11 , four months after the first confirmed case.
  • “Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan.

Texas Biomed at forefront of Sudan ebolavirus biomedical R&D

Retrieved on: 
Monday, December 19, 2022
Office of Inspector General, U.S. Department of Health and Human Services, World Health Organization, Biomedical Advanced Research and Development Authority, Patient, Business development, BARDA, SAN, Administration, U.S. Department of Defense Strategy for Operating in Cyberspace, Southwest National Primate Research Center, BSL-4, Texas Biomedical Research Institute, FDA, Safety, Multimedia, Government, Infection, Vaccine, Doctor of Philosophy, Development, Research, Sabin Vaccine Institute, Pharmaceutical industry

A vaccine and therapeutic tested at Texas Biomed have been sent to Uganda to help control the Sudan ebolavirus outbreak.

Key Points: 
  • A vaccine and therapeutic tested at Texas Biomed have been sent to Uganda to help control the Sudan ebolavirus outbreak.
  • Sudan ebolavirus is one of six known Ebola species, with a fatality rate ranging between 41% and 100%.
  • Texas Biomed will continue to help advance vaccines and therapies for Sudan ebolavirus.
  • Through basic research, preclinical testing and innovative partnerships, Texas Biomed accelerates diagnostics, therapies and vaccines for the world's deadliest pathogens.

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

Retrieved on: 
Wednesday, December 7, 2022
Fever Dream, Gold medal, Rising Star, RSV, Friends, Respiratory syncytial virus, Mumps, R, Head, Merck & Co., Coronavirus, BioNTech, Gold, Mentorship, Health, Sabin, Partnership, Inbar Lavi, FDA, DRS, Rotavirus, Pfizer, Public health, Ecosystem, HPV, Harvard T.H. Chan School of Public Health, Vaccine, Degenerative disease, Doctor of Philosophy, Sabin Vaccine Institute, Streptococcus pneumoniae, Education, STEM, RNA transfection, Infection, Pneumonia, Measles, Research, Cervical cancer, Rubella, Pandemic, Rising Star Award, COVID-19, Policy, Pharmaceutical industry

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

Key Points: 
  • The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.
  • This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc.
  • Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine.
  • “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics.

Texas Biomedical Research Institute in San Antonio Added to National Readiness and Preparedness Network

Retrieved on: 
Tuesday, December 13, 2022
Laboratory, Bioterrorism, United States Department of Health and Human Services, State, Infection, Development, Biomedical Advanced Research and Development Authority, Human services, Partnership, ASPR, IDIQ, Pandemic, Research, Texas Biomedical Research Institute, Office of Inspector General, U.S. Department of Health and Human Services, Southwest National Primate Research Center, BARDA, Sabin Vaccine Institute, DHHS, COVID-19, Administration, Human, Vaccine, National Primate Research Center, Federal, SAN, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmaceutical industry

SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network.

Key Points: 
  • SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- The federal agency that protects against pandemics and bioterrorism has elevated Texas Biomedical Research Institute into the top ranks of its national readiness and preparedness network.
  • "This is a huge win for San Antonio and Texas Biomed not to mention for the whole state," said State Sen. Jose Menendez, D-San Antonio.
  • Texas Biomed is the nation's only non-profit, independent research institute with the highest-level biocontainment laboratories, a national primate research center and over 80 years of experience.
  • Our San Antonio campus hosts high containment laboratories and the Southwest National Primate Research Center.